A5016116687- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- IL-33, ST2, and ILC Pathways
- Eosinophilic Esophagitis
The Ohio State University Wexner Medical Center
2025
National Institutes of Health
2016
National Institute of Arthritis and Musculoskeletal and Skin Diseases
2016
Innate lymphoid cells (ILC) play an important role in many immune processes, including control of infections, inflammation, and tissue repair. To date, little is known about the metabolism ILC whether these can metabolically adapt response to environmental signals. Here we show that type 2 innate (ILC2), mediators barrier immunity, predominantly depend on fatty acid (FA) during helminth infection. Further, situations where essential nutrient, such as vitamin A, limited, ILC2 sustain their...
Checkpoint inhibitor pneumonitis (CIP) that develops following immune checkpoint (ICI) treatment can be difficult to distinguish from other common etiologies of lung inflammation in cancer patients. Here, we evaluate the bronchoalveolar lavage fluid (BAL) for potential biomarkers specific CIP. We conducted a retrospective study patients who underwent standard care bronchoscopy compare cytokines interest between with and without CIP immune-mediated pulmonary diseases. Pulmonary diagnoses were...
Immune checkpoint inhibitors (ICIs) are first line treatment for advanced lung cancer. Tobacco use is a shared risk factor cancer and chronic obstructive pulmonary disease (COPD). Although many patients with COPD receive ICIs, the impact of ICIs on unknown. Here, we evaluated whether ICI was associated increased burden. We conducted retrospective cohort study without preexisting who received from 2011-2021 at The Ohio State University (OSU). For all patients, number steroid courses...